Breaking News
9 hours ago
Vaibhavi M.
Ocugen, Inc. completes dosing in Phase 2/3 GARDian3 trial of OCU410ST for Stargardt disease, advancing its gene therapy toward planned BLA submission after positive progress.
Vaibhavi M.
Vertex Pharmaceuticals Incorporated expands FDA approval for ALYFTREK and TRIKAFTA, enabling broader treatment of cystic fibrosis across more CFTR variants and younger patient populations.
Vaibhavi M.
Thermo Fisher Scientific Inc. launches CHOvantage GS platform to accelerate biologics development, enabling high-yield CHO cell line creation with faster timelines and scalable manufacturing support.
Vaibhavi M.
Eli Lilly and Company gains FDA approval for Foundayo (orforglipron), an oral drug for obesity, showing significant weight loss in trials and expanding treatment access options.
Vaibhavi M.